Innovative Cancer Therapies: Targeting Oncogenic Pathways Through Placental Immunology, PROTAC Technology, and Kinase Degradation
Overview
Overview
Journal
ACS Med Chem Lett
Publisher
American Chemical Society
Specialty
Chemistry
Date
2024 Dec 18
PMID
39691519
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
Abstract
Recent advancements in cancer therapy have led to groundbreaking approaches targeting critical oncogenic pathways. This Patent Highlight explores four essential patents that focus on modulating ligand-receptor interactions from placental immunology, degrading RAF proteins with MEK1/2 degraders, and employing PROTAC technology to degrade Cyclin D, CDK4, and CDK6 proteins. These innovations aim to overcome traditional therapy limitations and address resistance in cancers such as breast, lung, and RAS-altered cancers. This publication examines these inventions' mechanisms, findings, and implications in modern cancer treatment.
References
1.
Pandey P, Khan F, Upadhyay T, Sharangi A
. Deciphering the Immunomodulatory Role of Cyclin-Dependent Kinase 4/6 Inhibitors in the Tumor Microenvironment. Int J Mol Sci. 2023; 24(3).
PMC: 9916547.
DOI: 10.3390/ijms24032236.
View
2.
Wang X, Zhao S, Xin Q, Zhang Y, Wang K, Li M
. Recent progress of CDK4/6 inhibitors' current practice in breast cancer. Cancer Gene Ther. 2024; 31(9):1283-1291.
PMC: 11405274.
DOI: 10.1038/s41417-024-00747-x.
View
3.
Rezaeian A, Inuzuka H, Wei W
. Insights into the aberrant CDK4/6 signaling pathway as a therapeutic target in tumorigenesis. Adv Protein Chem Struct Biol. 2023; 135:179-201.
PMC: 10976432.
DOI: 10.1016/bs.apcsb.2022.11.009.
View
4.
Magge T, Rajendran S, Brufsky A, Foldi J
. CDK4/6 inhibitors: The Devil is in the Detail. Curr Oncol Rep. 2024; 26(6):665-678.
DOI: 10.1007/s11912-024-01540-7.
View
5.
Awada A, Ahmad S
. Therapeutic Prospects of Abemaciclib for Patients with Endometrial Cancer. Curr Oncol. 2024; 31(9):5374-5383.
PMC: 11431580.
DOI: 10.3390/curroncol31090397.
View